MAP2K7 and melanoma: A multicenter real-world study of the German Dermatologic Cooperative Oncology Group explored RFS, overall and melanoma-specific survival (MSS) and the response to subsequent treatment in 589 stage III melanoma patients undergoing adjuvant treatment with PD1 inhibitors or with BRAF+MEK inhibitors [64].